Abstract:Background: Worldwide, in the absence of standard pediatric prescribing information, clinicians often use medicines in children in a dosage form or for an indication that has not been approved for use. Inadequate clinical trials increase exposure to drugs that lack safety-efficacy data in pediatric population. Hence, off-label and unlicensed drug use must be regarded as a patient safety-issue that is known to be associated with increased risks of adverse drug reactions apart from under- or overdosing due to lack of pharmacokinetic data. This review aims to give an overview of the worldwide reported rates of off-label and unlicensed drug use in different patient populations in pediatric settings, with a brief summary of the related adverse drug reactions (ADRs) and a discussion of the existing regulatory provisions and possible solutions for ensuring safe use of medicines in children. Method: Literature searches were conducted and we included studies that evaluated unlicensed or off-label drug use in various pediatric patient populations. The definition of off-label drug use and unlicensed drug varied between different studies. Results: Fourteen studies from different countries were included in the review and were grouped as: studies conducted in the patients admitted in neonatal intensive care units, in pediatric wards, in hospitalized children and in pediatric outpatient settings. The number of patients studied ranged from 34 in neonatal intensive care units to 355 409 hospitalized children. Many studies reported high rates of off-label (9% to 78.7%) and unlicensed (0.3% to 35%) drug use in different pediatric patient settings. Conclusion: Given the prevalence of unlicensed and off-label drug use, the cooperation of various stakeholders including health professionals, pediatric population and their parents/caregivers, regulatory authorities, and the pharmaceutical industry is integral to instituting individual measures to avoid exposing children to unnecessary risks and avoid depriving them of potentially effective pharmacotherapy. Initiatives to encourage clinical trials for licensing drug use in children by providing market exclusivity and patent extension could aid in bridging the gap between approval and contemporary drug prescribing practices. Enforcement of legislations in the drug development process and subsequent pharmacovigilance could improve the quality of information and accountability of pharmaceutical industry to support and facilitate drug research in children.

No population left behind: Improving paediatric drug safety using informatics and systems biology

A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Research progress in drug toxicology based on systems biology

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Extent of Safety Database in Pediatric Drug Development: Types of Assessment, Analytical Precision, and Pathway for Extrapolation through On-Target Effects

Signalling Paediatric Side Effects using an Ensemble of Simple Study Designs

Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics.

Precision Dosing Management with Intelligent Computing in Digital Health

Current Knowledge, Challenges and Innovations in Developmental Pharmacology: A Combined Conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

Dosage individualization in children: integration of pharmacometrics in clinical practice

Challenges in the assessment of adverse drug reactions in children and neonates

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Understanding the informal aspects of medication processes to maintain patient safety in hospitals: a sociotechnical ethnographic study in paediatric units

Pediatric Medication Safety in Adult Community Hospital Settings: A Glimpse Into Nationwide Practice

Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children

The role of communication in paediatric drug safety

Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies

Pediatric Off-Label and Unlicensed Drug Use and Its Implications

Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance

Idrug: Pediatric Drug Interaction Modeling and Risk Evaluation Leveraging Prescription Big Data.

[PERSPECTIVES] Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress